Leonard T Heffner
Overview
Explore the profile of Leonard T Heffner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1043
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kaufman J, Mina R, Shah J, Laubach J, Nooka A, Lewis C, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Aug;
20(12):797-803.
PMID: 32819881
Introduction: Bortezomib plus lenalidomide and dexamethasone (VRD) is a standard induction therapy for newly diagnosed multiple myeloma (NDMM) patients. Given preclinical and clinical data suggesting the synergistic activity of the...
12.
Kong J, Winton E, Heffner L, Gaddh M, Hill B, Neely J, et al.
J Clin Med
. 2020 May;
9(5).
PMID: 32443762
We sought to evaluate the outcomes of chronic phase (CP) chronic myeloid leukemia (CML) in an era where five tyrosine kinase inhibitors (TKIs) are commercially available for the treatment of...
13.
Joseph N, Kaufman J, Dhodapkar M, Hofmeister C, Almaula D, Heffner L, et al.
J Clin Oncol
. 2020 Apr;
38(17):1928-1937.
PMID: 32298201
Purpose: The combination of lenalidomide, bortezomib, and dexamethasone (RVD) is a highly effective and convenient induction regimen for both transplantation-eligible and -ineligible patients with myeloma. Here, we present the largest...
14.
Jillella A, Arellano M, Heffner L, Gaddh M, Langston A, Khoury H, et al.
Hematol Rep
. 2019 Dec;
11(4):8395.
PMID: 31871613
No abstract available.
15.
Cohen J, Wei L, Maddocks K, Christian B, Heffner L, Langston A, et al.
Cancer
. 2019 Dec;
126(6):1235-1242.
PMID: 31821549
Background: Both gemcitabine and bendamustine have been evaluated in patients with recurrent/refractory Hodgkin lymphoma but to the authors' knowledge not as a doublet. The authors completed a phase 1/2 trial...
16.
Schmidt T, Barwick B, Joseph N, Heffner L, Hofmeister C, Bernal L, et al.
Blood Cancer J
. 2019 Nov;
9(12):94.
PMID: 31767829
Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the...
17.
Kahl B, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, et al.
Clin Cancer Res
. 2019 Nov;
25(23):6986-6994.
PMID: 31685491
Purpose: ADCT-402 (loncastuximab tesirine) is an antibody-drug conjugate comprising a CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human study evaluated the safety and preliminary clinical activity of loncastuximab tesirine in patients...
18.
Mahadevan D, Lanasa M, Farber C, Pandey M, Whelden M, Faas S, et al.
J Immunother Cancer
. 2019 Aug;
7(1):227.
PMID: 31443741
Purpose: Samalizumab is a novel recombinant humanized monoclonal antibody that targets CD200, an immunoregulatory cell surface member of the immunoglobulin superfamily that dampens excessive immune responses and maintains self-tolerance. This...
19.
Nooka A, Joseph N, Kaufman J, Heffner L, Gupta V, Gleason C, et al.
Cancer
. 2019 May;
125(17):2991-3000.
PMID: 31090928
Background: The efficacy of daratumumab (DARA) both as a monotherapy and in combination with standard-of-care regimens in multiple myeloma (MM) has been established in clinical trials. This article presents a...
20.
Kaufman J, Mina R, Jakubowiak A, Zimmerman T, Wolf J, Lewis C, et al.
Blood Cancer J
. 2019 Jan;
9(1):3.
PMID: 30610196
Proteasome (PIs) and hystone deacetylase inhibitors (HDACis) have previously shown synergistic activity in the treatment of relapesed/refractory multiple myeloma (RRMM) patients. In this phase 1 study, we combined carfilzomib, a...